{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:40:07Z","timestamp":1761561607253},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T00:00:00Z","timestamp":1326153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Hyperhaemolytic transfusion reaction (HHTR) has been well described in patients with sickle cell disease (SCD). It is characterised by a decrease in haemoglobin concentration to levels below those before transfusion and a fall in the absolute reticulocyte count. As red blood cells (RBC) alloantibodies are typically not detected in post\u2010transfusion samples in acute forms of HHTR, we have previously proposed that both the transfused and autologous RBCs cells (HbSS\/reticulocytes) are destroyed by activated macrophages.<\/jats:p><jats:p><jats:bold>Case reports:<\/jats:bold> We report a patient with SCD who presented with vaso\u2010occlusive sickle cell crisis and developed a severe HHTR attributable to anti\u2010Fy3. In addition to the usual supportive measures, the patient was treated with intravenous immunoglobulin (IVIG) and steroids. Serum ferritin levels were measured as an aspecific marker of macrophage activation.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Steroids and IVIG were effective in managing HHTR. Ferritin levels were high at the time of haemolysis, (&gt;10000 \u00b5g L<jats:sup>\u22121<\/jats:sup>) whereas recovery and cessation of haemolysis correlated with a decrease in ferritin levels.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Serum ferritin values &gt;10 000 \u00b5g L<jats:sup>\u22121<\/jats:sup> are considered pathognomic for conditions characterised by abnormal macrophage activation. In our case, serum ferritin levels correlate well with the disease activity and clinical response. This further supports our previous proposal that the activated macrophages play an important role in HHTR. Serum ferritin is a nonspecific marker of inflammation. A rapid specific bio\u2010marker to measure the activity of macrophages in SCD in HHTR is desirable, and this area warrants further investigation.<\/jats:p>","DOI":"10.1111\/j.1365-3148.2011.01131.x","type":"journal-article","created":{"date-parts":[[2012,1,10]],"date-time":"2012-01-10T12:35:46Z","timestamp":1326198946000},"page":"137-141","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Measurement of macrophage marker in hyperhaemolytic transfusion reaction: a case report"],"prefix":"10.1111","volume":"22","author":[{"given":"N.","family":"Win","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Needs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.\u2010W.","family":"Chia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Stasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00007.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2006.00679.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood.V96.7.2451","article-title":"Activated monocytes in sickle cell disease potential role in the activation of vascular endothelium an vaso\u2010occlusion.","volume":"96","author":"Belcher J.D.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.6.3077"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02199.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470987018"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2005.00608.x"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000067908"},{"key":"e_1_2_8_10_1","first-page":"299","article-title":"Haemophagocytic syndromes in adults: current concepts and challenges ahead.","volume":"135","author":"Emmenenegger U.","year":"2005","journal-title":"Swiss Medical Weekly"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/35011084"},{"key":"e_1_2_8_12_1","first-page":"148.","article-title":"Hyperhaemolysis associated with red cell transfusion in sickle cell disease.","volume":"33","author":"Friedman D.F.","year":"1993","journal-title":"Transfusion"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37497265334.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2008.00891.x"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V64.3.733.733","article-title":"Phagocytosis of sickle erythrocyte: Immunological and oxidative determinants of haemolytic anemia.","volume":"64","author":"Hebbel R.P.","year":"1984","journal-title":"Blood"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00306-10"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37497265337.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/35051594"},{"key":"e_1_2_8_19_1","first-page":"1027","article-title":"High ferritin and low glycosylated ferritin may also be a marker of excessive macrophage activation.","volume":"30","author":"Lambotte O.","year":"2003","journal-title":"Journal of Rheumatology"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000204892"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200024605082"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.21307\/immunohematology-2019-392","article-title":"Acute hemolytic transfusion reaction secondary to anti\u2010Fy3.","volume":"21","author":"Olteanu H.","year":"2005","journal-title":"Immunohematology"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1997.37497265338.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.21307\/immunohematology-2019-263","article-title":"Hyperhemolytic transfusion reaction attributable to anti\u2010Fy3 in a patient with sickle cell disease.","volume":"24","author":"Reyes M.A.","year":"2008","journal-title":"Immunohematology"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1182\/blood.V76.7.1431.1431","article-title":"Transfusion and alloimmunisation in sickle cell disease. The Cooperative Study of sickle cell disease.","volume":"76","author":"Rosse W.F.","year":"1990","journal-title":"Blood"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2004.00318.x"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.111.6.e661"},{"key":"e_1_2_8_28_1","first-page":"482.","article-title":"Anti\u2010Fya preceding anti\u2010Fy3 or \u2010Fy5: a study of five cases [Abstract].","volume":"25","author":"Vengelen\u2010Tyler V.","year":"1985","journal-title":"Transfusion"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07494.x"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.09.2"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41030323.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10245330400001926"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01693.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2009.09.006"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/10715760400011692"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3148.2011.01131.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3148.2011.01131.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T20:27:25Z","timestamp":1697660845000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3148.2011.01131.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,10]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1365-3148.2011.01131.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3148.2011.01131.x","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,10]]},"assertion":[{"value":"2012-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}